Evidence map›Paper›PMID 21151154›Full record

ArticleAsian journal of andrology2011

Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.

Roberta Mazzucchelli, Doriana Morichetti, Marina Scarpelli, Aldo V Bono, Antonio Lopez-Beltran, Liang Cheng, Ziya Kirkali, Rodolfo Montironi

Open access · goldAbstract read
In one paragraph

Article in Asian journal of andrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Roberta MazzucchelliSection of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona 60126, Italy.
Doriana Morichetti
Marina Scarpelli
Aldo V Bono
Antonio Lopez-Beltran
Liang Cheng
Ziya Kirkali
Rodolfo Montironi
Marche Polytechnic University · ITDokuz Eylül University · TRHospital Universitario Reina Sofía · ESIndiana University – Purdue University Indianapolis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to examine the tissue expression and localisation of the somatostatin receptors (SSTRs) in hormone-refractory (HR) prostate cancer (PCa). Five SSTRs were evaluated immunohistochemically in 20 radical prostatectomies (RPs) with Gleason score (GS) 3+3=6 PCa, in 20 RPs with GS 4+4=8 and 4+5=9 PCa, and 20 transurethral resection of the prostate specimens with HR PCa. The mean values in the cytoplasm (all five SSTRs were expressed), membrane (only SSTR3 and SSTR4 were expressed) and nuclei (only SSTR4 and SSTR5 were expressed) of the glands in HR PCa were 20-70% lower than in the other two groups, the differences being statistically significant. All five SSTRs were expressed in the smooth muscle and endothelial cells of HR PCa, the mean values being lower than in the other two groups. In conclusion, this study expands our knowledge on the expression and localisation of five SSTRs in the various tissue components in the HR PCa compared with hormone-sensitive PCa.

Indexed as

AgedAged, 80 and overAndrogen AntagonistsDrug Resistance, NeoplasmEndothelial CellsEpithelial CellsHumansImmunohistochemistryMaleMiddle AgedMyocytes, Smooth MuscleNeoplasms, Hormone-DependentOrchiectomyProstatectomyProstatic NeoplasmsReceptors, SomatostatinAndrogen AntagonistsReceptors, Somatostatinsomatostatin receptor 2somatostatin receptor 3somatostatin receptor 5somatostatin receptor subtype-4somatostatin receptor type 1

Identifiers

PMID21151154
PMCPMC3739180
OpenAlexW2138992397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.